CD8A and Langerhans cell histiocytosis: The aim of this study was therefore to (i) assess the presence and clinical impact of lesional CD8+ T cells in (HLA and BRAFV600E) genotyped LCH-patients, and (ii) to investigate whether BRAFV600E derived neopeptides are presented by HLA class I molecules and could be recognized by such CD8+ T cells.